Menu Back toSession-0306-Clinical-Science-II-IMCT-Latest-Guidance-Population-PK-Value-in-Development

The 7th DIA China Annual Meeting

Session 0306 Clinical Science - II - IMCT Latest Guidance: Population PK Value in Development

Session Chair(s)

Paul  Dai, MD

Paul Dai, MD

  • Head of Clinical Operations
  • TDC, Asia, Takeda, China

Early Phase Development Design Strategy3 DIA7 Bashaw (NXPowerLite Copy)


E. Dennis  Bashaw, PharmD

Early Phase Development Design Strategy3 DIA7 Bashaw (NXPowerLite Copy)

E. Dennis Bashaw, PharmD

  • Senior Science Advisor, Office of Clinical Pharmacology
  • FDA, United States
Hartmut  Blode

Early phase development strategy & value of model based drug development

Hartmut Blode

  • Head of Clinical Pharmacology Asia/ Primary Care
  • Bayer Healthcare Co.,Ltd., China
Peiming  Ma

Considerations for First-in-Man (FIM) Studies

Peiming Ma

  • Senior Director, Clinical Pharmacology, R&D Center
  • GSK China, China

Contact us

For exhibition, advertising and hosting inquiry, please contact:
Jean XU:, or Sofie Peeters:
Tel: +86 10 5923 1096

For general inquiry, please contact DIA China office:
Tel: +86 10 5704 2650